Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Larimar Therapeutics Inc LRMR

Healthcare Biotechnology
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LRMR)

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

GlobeNewswire March 14, 2024

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

GlobeNewswire March 11, 2024

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire March 6, 2024

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 16, 2024

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

GlobeNewswire February 14, 2024

Larimar Therapeutics Announces Proposed Underwritten Public Offering

GlobeNewswire February 13, 2024

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

GlobeNewswire February 12, 2024

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 14, 2023

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

GlobeNewswire November 1, 2023
View More News ››

Opinion & Analysis (NDAQ:LRMR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LRMR)

Larimar Therapeutics Inc. (NASDAQ: LRMR) Leading the Way in

Just In: $LRMR Larimar Therapeutics Inc. (NASDAQ: LRMR) Leading the Way in Tuesday Trading Based on Percentage GainLarimar Therapeutics,...
whytestocks - February 13, 2024

Why Is Inherited Rare Disease Focused-Larimar Therapeutics S

Just In: $LRMR Why Is Inherited Rare Disease Focused-Larimar Therapeutics Stock Trading Lower Today? | BenzingaLarimar Therapeutics Inc@...
whytestocks - February 12, 2024

Larimar Therapeutics Reports Positive Top-line Data from Pha

BREAKING NEWS: $LRMR Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg...
whytestocks - February 12, 2024

Larimar Therapeutics Reports Positive Top-line Data from Pha

JUST IN: $LRMR Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of...
whytestocks - February 12, 2024

Biopharmaceutical Zafgen (ZFGN) Trading 44% Below Cash Value

Zafgen (NASDAQ:ZFGN) anounnced on 7/19/2016 that in order to concentrate effort and resources, it will drop one trial...
MiamiGent - July 24, 2016
View more Bullboard ››

Pulsar Helium Inc.

Pulsar Helium Inc.

Pulsar Helium Inc. is a Canada-based helium exploration and development company. The Company's assets include the flagship ...
View More »